Current Report Filing (8-k)
June 28 2022 - 9:17AM
Edgar (US Regulatory)
0001551152
false
Common Stock, $0.01 Par Value
ABBV
0001551152
2022-06-23
2022-06-23
0001551152
us-gaap:CommonStockMember
exch:XNYS
2022-06-23
2022-06-23
0001551152
exch:XCHI
us-gaap:CommonStockMember
2022-06-23
2022-06-23
0001551152
abbv:SeniorNotes1.500Percentdue2023Member
exch:XNYS
2022-06-23
2022-06-23
0001551152
abbv:SeniorNotes1.375Percentdue2024Member
exch:XNYS
2022-06-23
2022-06-23
0001551152
abbv:SeniorNotes1.250Percentdue2024Member
exch:XNYS
2022-06-23
2022-06-23
0001551152
abbv:SeniorNotes0.750Percentdue2027Member
exch:XNYS
2022-06-23
2022-06-23
0001551152
abbv:SeniorNotes2.125Percentdue2028Member
exch:XNYS
2022-06-23
2022-06-23
0001551152
abbv:SeniorNotes2.625Percentdue2028Member
exch:XNYS
2022-06-23
2022-06-23
0001551152
abbv:SeniorNotes2.125Percentdue2029Member
exch:XNYS
2022-06-23
2022-06-23
0001551152
abbv:SeniorNotes1.250Percentdue2031Member
exch:XNYS
2022-06-23
2022-06-23
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the
Securities
Exchange Act of 1934
Date of Report (Date of earliest event
reported): June 23, 2022
ABBVIE INC.
(Exact name of registrant as specified in its charter)
Delaware |
|
001-35565 |
|
32-0375147 |
|
|
|
|
|
(State or other Jurisdiction
of Incorporation) |
|
(Commission File Number) |
|
(IRS Employer
Identification No.) |
1 North Waukegan Road
North Chicago, Illinois 60064-6400
(Address of principal executive offices)(Zip Code)
Registrant’s telephone number, including area code: (847) 932-7900
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
¨ |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
¨ |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
¨ |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
¨ |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
Title of each class |
|
Trading Symbol(s) |
|
Name of each exchange on which registered |
Common Stock, $0.01 Par Value |
|
ABBV |
|
New York Stock Exchange Chicago Stock Exchange |
1.500% Senior Notes due 2023 |
|
ABBV23B |
|
New York Stock Exchange |
1.375% Senior Notes due 2024 |
|
ABBV24 |
|
New York Stock Exchange |
1.250% Senior Notes due 2024 |
|
ABBV24B |
|
New York Stock Exchange |
0.750% Senior Notes due 2027 |
|
ABBV27 |
|
New York Stock Exchange |
2.125% Senior Notes due 2028 |
|
ABBV28 |
|
New York Stock Exchange |
2.625% Senior Notes due 2028 |
|
ABBV28B |
|
New York Stock Exchange |
2.125% Senior Notes due 2029 |
|
ABBV29 |
|
New York Stock Exchange |
1.250% Senior Notes due 2031 |
|
ABBV31 |
|
New York Stock Exchange |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ¨
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨
Common Stock, $0.01 Par Value |
ABBV |
Item
5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements
of Certain Officers.
Robert
A. Michael, 51, has been appointed Vice Chairman and President, effective June 23, 2022. Mr. Michael has been AbbVie’s Vice Chairman,
Finance and Commercial Operations and Chief Financial Officer since December 2021. Mr. Michael previously served as AbbVie’s
Executive Vice President, Chief Financial Officer from October 2018 to December 2021, as AbbVie’s Vice
President, Controller from March 2017 until October 2018, as Vice President, Treasurer from 2015 to 2016, and as Vice President,
Controller, Commercial Operations from 2013 to 2015. Mr. Michael joined Abbott Laboratories in 1993 and held numerous positions
in the finance organization.
Scott
T. Reents, 55, has been appointed Senior Vice President, Chief Financial Officer, effective June 23, 2022. Mr. Reents previously
served as Vice President, Tax and Treasury from March 2019 to June 2022, as Treasurer from January 2020 to November 2020, and as
Vice President, Tax from January 2013 to March 2019. Mr. Reents joined Abbott Laboratories in 2008 and has been with AbbVie since
inception in 2013.
SIGNATURE
Pursuant to
the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
|
|
|
ABBVIE
INC. |
|
|
|
|
Date: |
June
28, 2022 |
By: |
/s/
Timothy J. Richmond |
|
|
|
Timothy
J. Richmond |
|
|
|
Executive
Vice President, Chief Human Resources Officer |
AbbVie (NYSE:ABBV)
Historical Stock Chart
From Jun 2024 to Jul 2024
AbbVie (NYSE:ABBV)
Historical Stock Chart
From Jul 2023 to Jul 2024